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ABSTRACT
Objective: To critically re-evaluate cases diagnosed as adult neuronal ceroid lipofuscinosis (ANCL)
in order to aid clinicopathologic diagnosis as a route to further gene discovery.
Methods: Through establishment of an international consortium we pooled 47 unsolved cases
regarded by referring centers as ANCL. Clinical and neuropathologic experts within the Consor-
tium established diagnostic criteria for ANCL based on the literature to assess each case. A panel
of 3 neuropathologists independently reviewed source pathologic data. Cases were given a final
clinicopathologic classification of definite ANCL, probable ANCL, possible ANCL, or not ANCL.
Results: Of the 47 cases, only 16 fulfilled the Consortium’s criteria of ANCL (5 definite, 2 prob-
able, 9 possible). Definitive alternate diagnoses were made in 10, including Huntington disease,
early-onset Alzheimer disease, Niemann-Pick disease, neuroserpinopathy, prion disease, and
neurodegeneration with brain iron accumulation. Six cases had features suggesting an alternate
diagnosis, but no specific condition was identified; in 15, the data were inadequate for classifi-
cation. Misinterpretation of normal lipofuscin as abnormal storage material was the commonest
cause of misdiagnosis.
Conclusions: Diagnosis of ANCL remains challenging; expert pathologic analysis and recent molec-
ular genetic advances revealed misdiagnoses in .1/3 of cases. We now have a refined group of
cases that will facilitate identification of new causative genes. Neurology® 2016;87:579–584
GLOSSARY
ANCL5 adult-onset neuronal ceroid lipofuscinosis; CGP5 custom gene panel;NCL5 neuronal ceroid lipofuscinosis;WES5
whole-exome sequencing.
Diagnosis of neurodegenerative diseases in younger adults is challenging due to the relative rarity
of the problem, the heterogeneous causes, and the frequent absence of noninvasive diagnostic
clues, raising the question of brain biopsy. The neuronal ceroid lipofuscinoses (NCLs) are
a group of storage diseases presenting from infancy to adulthood.1 The stored material is largely
made up of subunit c of mitochondrial adenosine triphosphate synthase or saposin proteins A
and D—that is, of proteins so hydrophobic that they require special mechanisms for their
breakdown and disposal.2
Adult-onset NCL (ANCL) is a particularly demanding diagnostic problem. Childhood NCLs
have well-characterized clinical patterns typically involving brain and eye, abundant storage in
readily accessible peripheral tissues such as skin, and largely solved molecular genetic causes.3–5
In contrast, ANCL can present in a variety of ways with progressive myoclonus epilepsy,
dementia, or motor disorders and shows limited storage in peripheral tissue. Stored material
is usually only found in a subset of neurons, with the accumulation of age-related lipofuscin
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often confused with pathologic storage.6–13
Furthermore, molecular genetic characteriza-
tion of ANCL is at an early stage. Hindered
by the small number of cases, and the clinical
and pathologic challenges, ANCL is poorly
understood.
Kufs disease is the best-known form of
ANCL; it differs from most childhood-onset
forms because there is no retinal involvement,
and the inheritance can be either recessive or
dominant. It is widely accepted that the uncom-
mon teenage-onset cases without retinal
involvement are grouped with adult-onset cases.
The clinical presentation is variable with 2
broad forms identified. Kufs type A presents
with progressive myoclonus epilepsy, whereas
Kufs type B presents with dementia and motor
signs.6,13 Recessive mutations in CLN614–16 and
dominant mutations in DNAJC517–19 can cause
Kufs type A; Kufs type B can be caused by
recessive mutations in CTSF.20,21 Rare cases of
ANCL with retinal involvement are described
due to mutations in PPT1 (CLN1),22,23
CLN5,24,25 and GRN.26 Finally, some patients
with CLN3 mutations present with neurologic
manifestations in adult life, on a background of
visual failure in childhood.27
Despite these important molecular discover-
ies, many reported cases that receive a diagnosis
of ANCL remain unsolved. As ANCL is rare,
we formed a consortium to combine putative
unsolved cases from centers around the world
and analyzed them as one large cohort. We
aimed to refine the clinical spectrum of late-
onset NCL by implementing an expert clinical
and pathologic review process, followed by con-
sensus diagnosis. Here we report our somewhat
surprising results, in particular, the frequent
misdiagnosis of a broad spectrum of neurologic
disorders as Kufs disease. Our eventual aim is to
discover the remaining molecular causes of
ANCL.
METHODS Participants. We established the ANCL Gene
Discovery Consortium encompassing researchers with clinical, neu-
ropathologic, and molecular genetic expertise in ANCL from the
United Kingdom, Europe, United States, Canada, and Australia.
Consortium members pooled 47 unrelated, unsolved cases
into a shared database. These cases had been referred to individual
Consortium researchers for molecular genetic studies over a 20-
year period because of diagnosis or putative diagnosis of ANCL.
Clinicopathologic support for an ANCL diagnosis varied consid-
erably in these cases that remained unsolved despite study by
a variety of molecular genetic and enzymatic assays over time.
For familial cases, only the proband was included. No attempt
was made to sequence all known NCL genes before entry into
the study.
Standard protocol approvals, registrations, and patient
consents. Local institutional review boards at each contributing
site approved this research. Participants or their guardians pro-
vided informed consent.
Diagnostic criteria. We developed initial diagnostic criteria
based on a combination of clinical and pathologic features. These
criteria were based on review of the literature and the clinical
experience of Consortium members.6–13
Clinical and pathologic review of cases. Strenuous attempts
were made to source detailed clinical data from treating clinicians.
We deliberately used broad clinical criteria (table 1) that allowed
for retinal involvement.
Neuropathologic diagnosis remains the gold standard for this
group of disorders. A panel of 3 expert neuropathologists (J.F.S.,
S.C., G.W.A.) developed criteria to classify the pathologic data as
definite, probable, or possible NCL (table 1). Images of the path-
ologic material, where available, were subsequently shared with
each of the 3 neuropathologists. They provided independent
opinions, which were then discussed, and a consensus on the
classification reached.
Overall classification of cases. Each case was given a final
classification of definite ANCL, probable ANCL, possible ANCL,
or not ANCL based on clinical and pathologic data. This occurred
via regular Consortium teleconferences where the clinical criteria
and pathologic classification were integrated to determine an overall
classification (table 2).
Table 1 Adult-onset neuronal ceroid lipofuscinosis: Clinical and pathologic
criteria
Clinical criteria (all 4 criteria required)
Age at onset between 12 and 60 years
Normal development and cognition prior to disease onset
Presence of at least 2 of the following:
Seizures or myoclonus
Progressive cognitive decline
Ataxia
Pyramidal or extrapyramidal motor signs
Documented deterioration over more than 2 years
Pathologic criteria
Definite pathologic features
Ultrastructural demonstration of one or more characteristic membrane-bound storage
morphologies (granular osmiophilic deposits [GRODs], fingerprint profiles, curvilinear profiles,
or rectilinear complexes) in more than one cell type, including but not limited to eccrine
secretory and duct cells, endothelial cells, smooth and skeletal muscle cells, or neurons or
their proximal axons. Fingerprint profiles in vascular smooth muscle and pericytes are
excluded, since it has been shown that they accumulate there nonspecifically with aging35
Probable pathologic features
Ultrastructural demonstration of one or more characteristic membrane-bound storage
morphologies (GRODs, fingerprint profiles, curvilinear profiles, or rectilinear complexes) in
a single cell type AND
Demonstration, in standard histologic preparations, of cytoplasmic inclusions with broad-
range autofluorescence or Luxol fast blue positivity in well-differentiated sections in one or
more of above cell types, to a degree significantly greater than expected for age, OR
Demonstration, by standard immunohistochemistry, of characteristic cytoplasmic storage
material, i.e., subunit c of mitochondrial adenosine triphosphate synthase, saposin protein
A, or saposin protein D
Possible pathologic features (in absence of ultrastructural data)
Demonstration, in standard histologic preparations, of cytoplasmic inclusions with broad-
range autofluorescence or Luxol fast blue positivity in well-differentiated sections in one or
more of the above cell types, to a degree significantly greater than expected for age
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Molecular genetic studies. Screening for known ANCL genes
(CLN6, CTSF, DNAJC5, GRN, and PPT1) was performed by
both Sanger sequencing and high-throughput sequencing
technologies in the majority of the 16 cases (detailed in table
e-1 on the Neurology® Web site at Neurology.org). Genomic
DNA was extracted from venous blood using standard
methods. Briefly, for Sanger sequencing, coding exons and
flanking intronic regions including splice sites of the 3 genes
were PCR amplified using primers designed for all isoforms with
reference human gene transcripts (NCBI Gene; http://www.ncbi.
nlm.nih.gov/; primers available on request). Amplification reactions
were cycled on a Veriti Thermal Cycler (Applied Biosystems,
Carlsbad, CA) and bidirectional sequencing was completed using
BigDye v3.1 Terminator Cycle Sequencing Kit (Applied
Biosystems). Sequencing products were resolved using a 3730xl
DNA Analyzer (Applied Biosystems). Sequence chromatograms
were compared to published cDNA sequence with nucleotide
changes detected using Codon Code Aligner (CodonCode
Corporation, Dedham, MA).
A custom gene panel (CGP), designed to target coding regions
(6.88 Mb) of 3,616 OMIM genes with known phenotypes includ-
ing ANCL, and whole-exome sequencing (WES) was also per-
formed for the majority (table e-1). DNA enrichment was
performed according to the manufacturer’s protocol using either
SeqCap EZ Choice Library (Roche Nimblegen, Madison, WI) for
the CGP or Nimblegen SeqCap V3 (Roche Nimblegen) for WES.
DNA sequencing was performed on the captured barcoded DNA
libraries using either SOLiD 4 System (Applied Biosystems) or
Table 2 Adult-onset neuronal ceroid lipofuscinosis (ANCL) classification criteria
incorporating both clinical and pathologic criteria (see table 1) for 47
putative cases
ANCL
classification Clinicopathologic criteria
No. of
cases
Definite ANCL All clinical criteria met plus definite pathology classification 5a
Probable ANCL Atypical clinical presentation (e.g., late onset) plus definite
pathology classification
All clinical criteria met plus probable pathology classification
2
Possible ANCL Atypical clinical presentation plus probable pathology
classification
All clinical criteria met plus possible pathology classification
9
Not ANCL Clinical, pathologic, or molecular data strongly suggesting an
alternate diagnosis
Review of images or source material suggests no evidence
of neuronal ceroid lipofuscinosis
Pathology images unavailable (i.e., report only)
31
aOne case had a compound heterozygous CLN6 mutation.
Table 3 Summary of 10 cases with an initial diagnosis of adult-onset neuronal ceroid lipofuscinosis (ANCL) in which an alternate diagnosis
was later confirmed
Case Clinical features Initial ANCL diagnosis Diagnostic reevaluation Final diagnosis
KC23 Onset mid-20s with motor and intellectual
deterioration (dementia); no seizures;
progressive ataxia but no distinct chorea;
autosomal dominant family history
Clinical history consistent with ANCL;
skin biopsy interpreted as showing
fingerprint profiles
Pathology review: normal lipofuscin;
clinical review suggested Huntington
disease; genetic diagnosis: HTT expansion
Huntington disease
KC33 Onset 28 years with cognitive decline;
seizure history unknown; deceased in 40s
Clinical history consistent with ANCL; brain
biopsy interpreted as showing
autofluorescent inclusions and GROD-
like material
Pathology review: Normal lipofuscin;
genetic diagnosis: NPC1 mutation
Niemann-Pick
syndrome
KC51 Onset 34 years; dementia with frontal
features, subtle facial dyskinesia,
parkinsonian and mild cerebellar features
including limb ataxia; no seizures;
autosomal recessive family history
Clinical history consistent with ANCL;
skin biopsy interpreted as showing
fingerprint profiles in sweat glands
Pathology review: normal lipofuscin;
genetic diagnosis: PLA2G6 p.G551S
mutation
Neurodegeneration
with brain iron
accumulation
KC35 Onset 20s with progressive cognitive
decline followed by tremor, myoclonus,
and ataxia
Clinical history consistent with ANCL; skin
biopsy interpreted as showing membrane-
bound inclusions with granular material
Pathology review: images of source
material not available; genetic diagnosis:
c19orf12 mutation
Neurodegeneration
with brain iron
accumulation
KC10 Onset age 29 with rapidly progressing
dementia, motor deterioration, and
myoclonus
Clinical history consistent with ANCL; rectal
biopsy identified electron-dense structure
interpreted as fingerprints and curvilinear
pattern consistent with NCL
Pathology review: images of source
material not available; brain biopsy
revealed malignant lymphocytes
Cerebral
Lymphoma
KC24 Onset 22 years; myoclonus and tonic-clonic
seizures; cognitive decline; personality
change; unsteady gait from early 20s
leading to wheelchair dependence;
deceased at 26 years
Clinical history consistent with ANCL;
postmortem brain biopsy interpreted as
consistent with ceroid lipofuscinosis
Pathology review: extensive lesion of the
thalamus consistent with “familial” fatal
insomnia; immunohistochemistry: PrPSc
positive; genetic diagnosis: PRNP
insertion c.154_177(6_13)
Prion disease
KC29 Onset at 13 years with myoclonus; tonic-
clonic seizures and absences at 15 years;
progressive ataxia; wheelchair-bound at
22 years; late ophthalmoplegia; mild
learning disability
Clinical history consistent with ANCL;
skin and muscle biopsy negative
Pathology review: images of source
material not available; genetic diagnosis:
hypothesis free whole exome sequencing
showed SACS p.P2798Q; p.T458I
mutation36
Autosomal
recessive spastic
ataxia of
Charlevoix-
Saguenay
KC8 Onset at 33 years with gait ataxia and
subsequent dementia, dystonia, and
psychiatric symptoms; no seizures;
autosomal dominant family history
Clinical history consistent with ANCL;
premortem biopsies not done
Autopsy revealed classical Alzheimer
disease; genetic diagnosis: PSEN1
p.S170F; CTSD p.A58V37
Early-onset familial
Alzheimer disease
KC21 Onset at 13 years with behavioral changes
(frontal dysfunction) and declining school
performance; myoclonus with occasional
tonic-clonic seizures and poor coordination
Clinical history consistent with ANCL;
no pathology (biopsy not done)
Genetic diagnosis: hypothesis free whole
exome sequencing showed SERPINI1
p.G392E mutation36
Neuroserpinopathy
KC7 Onset age 19 years; progressive disease
with myoclonus, epilepsy, and ataxia
Clinical history consistent with ANCL; skin,
muscle, and brain biopsy negative
Pathology review: images of source
material not available; genetic diagnosis:
MTND3 mutation
Leigh syndrome
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Illumina HiSeq 1500. Data analysis was performed as previously
described.28 The data were inspected for variations in known
ANCL genes and the search for novel genes is ongoing.
Molecular diagnosis of cases initially suspected of having
ANCL, where other disorders were later established, were per-
formed at a number of commercial and research laboratories using
standard techniques.
RESULTS Of the 47 Consortium cases, 16 cases ful-
filled the Consortium’s clinical and pathologic criteria
for definite, probable, or possible ANCL disease (table
2). Of the 16 cases, 8 (2 definite) presented with seizures
as a main feature, usually with a progressive myoclonus
epilepsy (Type A Kufs). The remaining 8 cases (3 def-
inite) presented with dementia and motor signs (Type B
Kufs). None of the ANCL cases had retinal involve-
ment. The mean age at onset was 35 years (median
35.5 years). There were 2 clusters; 6 had onset in the
second decade of life and 10 in the fourth decade or
later. Both Type A and Type B cases were represented in
the 2 age clusters. Two cases fell outside of our arbitrary
12- to 60-years range for disease onset (onset at 10 and
62 years); these cases were considered clinically atypical
and classified overall as possible ANCL (table 2).
A family history suggestive of dominant inheri-
tance was found in 4/16 ANCL cases; in 12, there
was no family history. DNAJC5 mutations were not
found in the 4 dominant cases or the 10 other cases
that had this gene sequenced. CLN6 and CTSF,
known causes of recessive ANCL, were sequenced
in 15 cases and 1 case had probable pathogenic com-
pound heterozygous CLN6 variants identified. This
patient was classified as definite ANCL with a Type A
presentation. This leaves a subset of 15 genetically
unsolved ANCL cases (4 definite).
Our criteria for ANCL were not met in 31/47
(66%) cases, including 2 cases previously published
in detail as having ANCL.29,30 In 10 of these 31 cases,
detailed review with further investigation established
definitive alternate diagnoses (table 3). The main rea-
son for misdiagnosis as ANCL was overinterpretation
of normal age-related lipopigment as pathologic stor-
age material (figure). Six cases had features suggesting
that ANCL was not the correct diagnosis. Two of these
had storage material without the characteristics of the
lipopigment seen in NCL, but a specific diagnosis
could not be made. Two had other neuropathologic
abnormalities, again without leading to a specific diag-
nosis. In 2 cases, biopsy material reported as suggestive
of NCL was considered nonspecific on review, and the
clinical features were atypical. In the remaining 15
cases, the clinical and pathologic data were inadequate
for classification.
DISCUSSION In this study of 47 cases considered to
have ANCL, we found that the diagnosis could be sup-
ported in only 16 cases; of these, 9 were considered pos-
sible cases. Moreover, ANCL was confidently excluded
in 16 cases, of which 10 had secure alternative diagno-
ses established. The classification criteria developed by
the Consortium were useful in formalizing the
approach to problematic cases and has highlighted
the challenges and subtleties in diagnosing ANCL.
The pathologic diagnosis is challenging and is
compounded by the relative rarity of these disorders
such that most neuropathologists have very limited
experience with the condition. In general, misdiagno-
sis occurred by overinterpretation of ultrastructural
findings in biopsy samples, with failure to distinguish
Figure Pathologic diagnosis and misdiagnosis of adult-onset neuronal ceroid lipofuscinosis (ANCL)
(A) Electron micrograph of KC33 shows one of many deposits of lipofuscin in a cortical neuron. These deposits were orig-
inally considered to represent granular osmiophilic deposits (GRODs), leading to a diagnosis of ANCL. Lipid vacuoles, as seen
here, are numerous in lipofuscin, but not in GRODs, and the granules in lipofuscin are coarser and less uniform (bar5 5 mm).
The patient had cognitive decline beginning at age 28 years; NPC1 mutation was later found (table 3). (B) This electron
micrograph of KC15 shows fingerprint profiles from an eccrine secretory cell. The basic paired parallel line pattern even at
this magnification tends to appear as a single wide slightly fuzzy line, but the spacing, the wheeling ranks, and the focal
crystalline pattern where the ranks intersect (at the left of the asterisk) are very characteristic (bar 5 1 mm). Disease onset
was at 18 years with stimulus-sensitive and action-induced myoclonus, dementia, and parkinsonism on the background of
normal development. This case met out criteria for classification as definite ANCL. The molecular basis remains unknown.
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normal lipofuscin that accumulates with age, from
abnormal lipopigment seen in NCL, which may be
very limited in ANCL.6–13 In children, this distinction
is easier, contrasting abundant storage in disease
with minimal normal age-related pigment. Rather than
relying on the amount of lipopigment, accurate diag-
nosis depends on analysis of the particular ultrastruc-
tural features.7,31 In all late-onset neuronal storage
diseases, only a subset of neurons may be involved.
This becomes important when it comes to electron
microscopy on a brain biopsy. If the blocks have not
been trimmed to include involved neurons, the study
may be limited to normal neurons that inevitably con-
tain lipofuscin, and confusion with ANCL may result.
Importantly, the removal of these cases from the
cohort helps simplify the apparent clinical and patho-
logic heterogeneity of ANCL. The clinical profile of
our ANCL cases fit broadly into the previously
described categories of presentation as progressive
myoclonus epilepsy (Type A) and dementia withmotor
disturbances (Type B)6; the single case that was solved
molecularly with a CLN6 mutation had a Type A pre-
sentation, as has been previously described.14
The degree of genetic heterogeneity of ANCL re-
mains unclear. It is already known that contrary to
the childhood forms, which are essentially all recessive
disorders, the adult forms can have either recessive or
dominant inheritance.6,32,33 While it is now possible
to survey the whole exome (or genome) for genetic
variation with high-throughput sequencing technology,
determining which of the many thousand variants iden-
tified are pathogenic remains challenging. However,
this is still a good option for treating clinicians and
may avoid the need for brain biopsy should a plausible
variant be found in one of the known ANCL genes or
in a gene known to cause an alternative late-onset neu-
rologic disease. The efficacy of genetic testing for diag-
nostic purposes will only improve as further ANCL
genes are discovered. At this point in time, pathologic
diagnosis remains the gold standard practice.
Future research into the underlying genetic etiol-
ogy of the unsolved ANCL will be supported by the
removal of misdiagnosed cases that would hinder
these important efforts. By pooling together unrelated
ANCL cases that putatively may share the same caus-
ative gene, the genomic search space can be consider-
ably narrowed. This ongoing work, resulting in
a deeper understanding of the molecular genetic basis,
will provide improved guidance for the accurate
and early diagnosis of ANCL. We anticipate that
the recently accepted nomenclature for the NCL34
will be expanded as new genes are identified.
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